Genomic and epigenetic factors associated with diabetes resolution after Roux-en-Y...
| Grant number: | 16/19170-1 |
| Support type: | Scholarships in Brazil - Post-Doctorate |
| Effective date (Start): | April 01, 2017 |
| Effective date (End): | July 31, 2019 |
| Field of knowledge: | Health Sciences - Nutrition |
| Principal Investigator: | Maria Lucia Cardillo Corrêa Giannella |
| Grantee: | Priscila Sala Kobal |
| Home Institution: | Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
Abstract Roux-en-Y Gastric Bypass (RYGB) is an effective method to treat Obesity and its metabolic effects include early glycemic control, even before significant weight loss. However, in clinical practice it is common that some patients don't achieve complete Type 2 Diabetes (T2D) remission, or some of them have the T2D recurrence in long-term. The mechanisms involved in T2D early remission and late recurrence after RYGB are still poorly understood, but as part of the thematic study 2011/09612-3 early changes were identified (3 months post-op) in gastrointestinal (GI) genes expressions involved in glucose homeostasis. Currently it is known that gene expression is directly influenced by epigenetic events such as DNA methylation. Most typically, the DNA hypomethylation triggers an increase in gene expression, whereas hypermethylation decreases the gene expression. Based on these observations, this study may provide a valuable opportunity (given the universal limitation for collection of GI biopsies) of knowing the late behavior of tissue and systemic transcriptomic and epigenetic alterations induced b RYGB that may be related to T2D remission and its recurrence. For this, we intend to evaluate changes in GI gene expression 2 years after RYGB and compare them with those found in the 3 months postoperatively. In addition, we intend to evaluate epigenetic changes in the pre-op and post-op 3 months and 2 years of RYGB. Our data may be useful to identify genes related to T2D long-term recurrence, and also identify the epigenetic changes that may be interfering in T2D resolution and its recurrence in the group of non-responders patients to RYGB related to the improvement in glucose homeostasis. (AU) | |